US Supreme Court justices seemed to disagree on whether a biosimilar sponsor must wait until FDA approval to provide notice it intends to market its product and whether the sponsor must hand over its application and manufacturing process information to the innovator.
During oral arguments April 26 in Sandoz Inc. v. Amgen Inc., Chief Justice John Roberts Jr. and Justices Anthony Kennedy and Stephen Breyer appeared to favor Amgen's view...